Authored Content
The recently launched CHI Catalogue signals payer endorsement of high-cost breakthrough therapies supported by strong clinical evidence, real-world data, and guideline endorsement.
Given the uncertain challenge of future international price referencing by the US, Avalere Health considers implications for global market access.
To enable global access to GLP-1 AOMs, manufacturers must demonstrate multidimensional value along the full care continuum and across the range of obesity linked-indications.